[Medicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?]

J C Becker1, W Domschke, T Pohle

  • 1Medizinische Klinik und Poliklinik B, Universitätsklinikum Münster, Münster.

Der Internist
|November 1, 2006
PubMed

Insights

Preventing gastrointestinal tumors is challenging, with few approved drugs. Lifestyle changes and targeted interventions like Helicobacter pylori eradication and Hepatitis B vaccination are key strategies for high-risk individuals.

Area of Science:

  • Gastroenterology
  • Oncology
  • Preventive Medicine

Background:

  • Limited pharmacotherapy options exist for preventing gastrointestinal tumors.
  • Current prevention strategies often lack approval or validation in randomized trials.

Purpose of the Study:

  • To review current strategies for gastrointestinal tumor prevention.
  • To highlight the role of lifestyle modifications and targeted interventions.

Main Methods:

  • Review of existing literature on gastrointestinal tumor prevention.
  • Analysis of lifestyle factors, pathogen eradication, vaccination, and NSAID use.

Main Results:

  • Lifestyle modifications (smoking cessation, moderate alcohol, exercise, diet) are generally recommended.
  • Helicobacter pylori eradication is advised for high-risk individuals to prevent gastric cancer.
  • Hepatitis B vaccination and antiviral therapy are crucial for preventing hepatocellular carcinoma.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) are not generally recommended for prevention but may be considered for high-risk patients in clinical studies.

Conclusions:

  • Comprehensive strategies including lifestyle changes and targeted interventions are essential for gastrointestinal tumor prevention.
  • Further research is needed to define optimal NSAID use for high-risk populations.

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...